Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY

Institutional investor adds to stake in biopharmaceutical company

Mar. 17, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an institutional investor, has acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. The fund bought 3,500 shares of Alnylam's stock, valued at approximately $1,596,000, during the third quarter according to a recent SEC filing.

Why it matters

Alnylam Pharmaceuticals is a leading player in the RNAi therapeutics space, developing innovative treatments for rare and more prevalent conditions. The acquisition of new shares by a prominent institutional investor like Bamco Inc. NY suggests continued confidence in Alnylam's growth potential and pipeline.

The details

According to the SEC filing, Bamco Inc. NY acquired the 3,500 shares of Alnylam Pharmaceuticals during the third quarter. This adds to the institutional investor's existing position in the company. Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNAi therapeutics, using small interfering RNA (siRNA) technology to silence disease-causing genes.

  • Bamco Inc. NY acquired the 3,500 shares of Alnylam Pharmaceuticals during the third quarter.

The players

Bamco Inc. NY

An institutional investor that has acquired a new stake in Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of new shares in Alnylam Pharmaceuticals by a prominent institutional investor like Bamco Inc. NY underscores the continued market confidence in the company's RNAi therapeutics pipeline and growth potential within the biopharmaceutical industry.